{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:25:28Z","timestamp":1790717128570,"version":"4.1.0"},"reference-count":71,"publisher":"Impact Journals, LLC","issue":"31","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,10,13]]},"DOI":"10.18632\/oncotarget.5290","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T21:54:23Z","timestamp":1443563663000},"page":"31134-31150","source":"Crossref","is-referenced-by-count":41,"title":["HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide"],"prefix":"10.18632","volume":"6","author":[{"given":"Alessandro","family":"Canella","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector Cordero","family":"Nieves","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Oncology\/Hematology Fellowship, The Ohio State University, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Cascione","sequence":"additional","affiliation":[{"name":"Lymphoma & Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna S.","family":"Radomska","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Biomedical Sciences Graduate Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Stiff","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Consiglio","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA"},{"name":"Present Address: Sanford Burnham Prebys Medical Discovery Insitute, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Caserta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Rizzotto","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Zanesi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volinia","family":"Stefano","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Biosystems Analysis, LTTA, Department of Morphology, Surgery and Experimental Medicine, Universit\u00e0 degli Studi, Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balveen","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Dardinger Laboratory for Neuro-oncology and Neurosciences, The Ohio State University Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokui","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Center for Biostatistics, The Ohio State University, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA"},{"name":"Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne A.","family":"Efebera","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig C.","family":"Hofmeister","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Pichiorri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA"},{"name":"Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,9,25]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.hoc.2007.08.010","article-title":"Prognostic factors and staging in multiple myeloma","volume":"21","author":"San Miguel","year":"2007","journal-title":"Hematology\/oncology clinics of North America"},{"key":"2","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Chen-Kiang","year":"2009","journal-title":"Leukemia"},{"key":"3","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1182\/blood-2009-01-202010","article-title":"Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone","volume":"114","author":"Russell","year":"2009","journal-title":"Blood"},{"key":"4","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2009-11-255620","article-title":"Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006\u201366 with VRD maintenance","volume":"115","author":"Barlogie","year":"2010","journal-title":"Blood"},{"key":"5","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study","volume":"376","author":"Deliliers","year":"2010","journal-title":"Lancet"},{"key":"6","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Gertz","year":"2008","journal-title":"Blood"},{"key":"7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1470-2045(09)70313-4","article-title":"Towards a new standard of care for patients with myeloma?","volume":"11","author":"Gay","year":"2010","journal-title":"The lancet oncology"},{"key":"8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3816\/CLM.2009.n.035","article-title":"Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results","volume":"9","author":"Petrucci","year":"2009","journal-title":"Clinical lymphoma & myeloma"},{"key":"9","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1182\/blood-2009-08-239046","article-title":"Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients","volume":"115","author":"Witzig","year":"2010","journal-title":"Blood"},{"key":"10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/gcc.20660","article-title":"Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles","volume":"48","author":"Neri","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"key":"11","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1182\/blood-2009-08-237495","article-title":"Identification of microRNA expression patterns and definition of a microRNA\/mRNA regulatory network in distinct molecular groups of multiple myeloma","volume":"114","author":"Neri","year":"2009","journal-title":"Blood"},{"key":"12","doi-asserted-by":"crossref","first-page":"12885","DOI":"10.1073\/pnas.0806202105","article-title":"MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis","volume":"105","author":"Aqeilan","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"13","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3390\/cancers5020430","article-title":"Epigenetic modulating agents as a new therapeutic approach in multiple myeloma","volume":"5","author":"De Bruyne","year":"2013","journal-title":"Cancers"},{"key":"14","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1038\/bcj.2014.29","article-title":"The role of epigenetics in the biology of multiple myeloma","volume":"4","author":"Gronbaek","year":"2014","journal-title":"Blood cancer journal"},{"key":"15","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1073\/pnas.2536759100","article-title":"Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications","volume":"101","author":"Anderson","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"16","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/10428190701817258","article-title":"Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma","volume":"49","author":"Siegel","year":"2008","journal-title":"Leukemia & lymphoma"},{"key":"17","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood.V93.5.1658","article-title":"Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines","volume":"93","author":"Dalton","year":"1999","journal-title":"Blood"},{"key":"18","doi-asserted-by":"crossref","first-page":"26533","DOI":"10.1074\/jbc.M109.027466","article-title":"Hyaluronan-CD44 interaction with protein kinase C (epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells","volume":"284","author":"Gilad","year":"2009","journal-title":"J Biol Chem"},{"key":"19","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/cas.12271","article-title":"Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck","volume":"104","author":"Masuyama","year":"2013","journal-title":"Cancer science"},{"key":"20","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","article-title":"Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study","volume":"14","author":"Houp","year":"2013","journal-title":"The lancet oncology"},{"key":"21","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1200\/JCO.2012.46.7068","article-title":"Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma","volume":"31","author":"Anderson","year":"2013","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"22","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1182\/blood.V122.21.5392.5392","article-title":"A Phase II, Single-Center, Open-Label Study Of Oral Panobinostat In Combination With Lenalidomide and Weekly Dexamethasone In Patients With Multiple Myeloma","volume":"122","author":"Chari","year":"2013","journal-title":"Blood"},{"key":"23","first-page":"3986","article-title":"Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide\/Dexamethasone Relapsed\/Refractory Multiple Myeloma","volume":"118","author":"Siegel","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"24","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1158\/1078-0432.CCR-06-0429","article-title":"Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer","volume":"12","author":"Chen","year":"2006","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"25","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ijc.25660","article-title":"The novel histone deacetylase inhibitor, AR-42, inhibits gp130\/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells","volume":"129","author":"Farag","year":"2011","journal-title":"International journal of cancer Journal international du cancer"},{"key":"26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/leu.2013.174","article-title":"Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications","volume":"28","author":"Orlowski","year":"2014","journal-title":"Leukemia"},{"key":"27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0065-230X(08)60101-3","article-title":"CD44: structure, function, and association with the malignant process","volume":"71","author":"Ish-Shalom","year":"1997","journal-title":"Adv Cancer Res"},{"key":"28","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ajpath.2011.06.005","article-title":"Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome","volume":"179","author":"Bergh","year":"2011","journal-title":"Am J Pathol"},{"key":"29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/path.3031","article-title":"Interstitial guidance of cancer invasion","volume":"226","author":"Friedl","year":"2012","journal-title":"J Pathol"},{"key":"30","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1083\/jcb.200812060","article-title":"Acetylation and activation of STAT3 mediated by nuclear translocation of CD44","volume":"185","author":"Chen","year":"2009","journal-title":"The Journal of cell biology"},{"key":"31","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/sj.emboj.7601039","article-title":"RNA-binding IMPs promote cell adhesion and invadopodia formation","volume":"25","author":"Nielsen","year":"2006","journal-title":"EMBO J"},{"key":"32","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1182\/blood-2009-07-231985","article-title":"AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit","volume":"115","author":"London","year":"2010","journal-title":"Blood"},{"key":"33","doi-asserted-by":"crossref","first-page":"e10941","DOI":"10.1371\/journal.pone.0010941","article-title":"The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignanciesand","volume":"5","author":"Croce","year":"2010","journal-title":"PLoS One"},{"key":"34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/icb.2011.96","article-title":"Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer","volume":"90","author":"Villagra","year":"2012","journal-title":"Immunology and cell biology"},{"key":"35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1600-0609.2007.01014.x","article-title":"CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells","volume":"80","author":"Saito","year":"2008","journal-title":"European journal of haematology"},{"key":"36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature01957","article-title":"The nuclear RNase III Drosha initiates microRNA processing","volume":"425","author":"Kim","year":"2003","journal-title":"Nature"},{"key":"37","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nbt0308-293","article-title":"Digital mRNA profiling","volume":"26","author":"Surrey","year":"2008","journal-title":"Nat Biotechnol"},{"key":"38","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0092-8674(03)01018-3","article-title":"Prediction of mammalian microRNA targets","volume":"115","author":"Burge","year":"2003","journal-title":"Cell"},{"key":"39","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ng1536","article-title":"Combinatorial microRNA target predictions","volume":"37","author":"Rajewsky","year":"2005","journal-title":"Nat Genet"},{"key":"40","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/sj.emboj.7601039","article-title":"RNA-binding IMPs promote cell adhesion and invadopodia formation","volume":"25","author":"Nielsen","year":"2006","journal-title":"The EMBO journal"},{"key":"41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2407-10-59","article-title":"Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival","volume":"10","author":"Owen","year":"2010","journal-title":"BMC cancer"},{"key":"42","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.cell.2006.07.031","article-title":"A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes","volume":"126","author":"Rigoutsos","year":"2006","journal-title":"Cell"},{"key":"43","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"44","first-page":"157496","article-title":"Bone marrow microenvironment in multiple myeloma progression","volume":"2012","author":"Roccaro","year":"2012","journal-title":"Journal of biomedicine & biotechnology"},{"key":"45","first-page":"198539","article-title":"Immunological dysregulation in multiple myeloma microenvironment","volume":"2014","author":"Di Raimondo","year":"2014","journal-title":"Biomed Res Int"},{"key":"46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0305-7372(03)00077-X","article-title":"The tumor microenvironment: focus on myeloma","volume":"1","author":"Dalton","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"47","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1038\/leu.2012.140","article-title":"CD19-CD45 low\/\u2212 CD38 high\/CD138+ plasma cells enrich for human tumorigenic myeloma cells","volume":"26","author":"Weissman","year":"2012","journal-title":"Leukemia"},{"key":"48","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.beha.2010.09.002","article-title":"Immunophenotyping in multiple myeloma and related plasma cell disorders","volume":"23","author":"Morice","year":"2010","journal-title":"Best practice & research Clinical haematology"},{"key":"49","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1182\/blood-2009-01-198408","article-title":"MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma","volume":"113","author":"Ghobrial","year":"2009","journal-title":"Blood"},{"key":"50","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.leukres.2010.04.021","article-title":"Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia","volume":"35","author":"Kruk","year":"2011","journal-title":"Leuk Res"},{"key":"51","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1365-2141.1994.tb08302.x","article-title":"Cell surface expression and functional significance of adhesion molecules on human myeloma-derived cell lines","volume":"87","author":"Anderson","year":"1994","journal-title":"Br J Haematol"},{"key":"52","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1517\/14728222.2012.687374","article-title":"CD44: a validated target for improved delivery of cancer therapeutics","volume":"16","author":"Klostergaard","year":"2012","journal-title":"Expert Opin Ther Targets"},{"key":"53","first-page":"305","article-title":"Adhesion molecules","volume":"107","author":"Skubitz","year":"2002","journal-title":"Cancer Treat Res"},{"key":"54","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/sj.bjc.6605839","article-title":"Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression","volume":"103","author":"Li","year":"2010","journal-title":"Br J Cancer"},{"key":"55","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/sj.bjc.6605185","article-title":"Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression","volume":"101","author":"Li","year":"2009","journal-title":"Br J Cancer"},{"key":"56","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1158\/0008-5472.CAN-04-3478","article-title":"The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer","volume":"65","author":"Rodr\u00edguez-Rodr\u00edguez","year":"2005","journal-title":"Cancer Res"},{"key":"57","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1158\/0008-5472.CAN-13-3311-T","article-title":"miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt\/\u03b2-catenin\/BCL9 pathway","volume":"74","author":"Hideshima","year":"2014","journal-title":"Cancer Res"},{"key":"58","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Clarke","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"59","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/B978-0-12-800092-2.00010-1","article-title":"Hyaluronan-CD44 interaction promotes oncogenic signaling, microRNA functions, chemoresistance, and radiation resistance in cancer stem cells leading to tumor progression","volume":"123","author":"Li","year":"2014","journal-title":"Adv Cancer Res"},{"key":"60","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/onc.2011.222","article-title":"Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan\/CD44-activated head and neck squamous cell carcinoma cells","volume":"31","author":"Krueger","year":"2012","journal-title":"Oncogene"},{"key":"61","doi-asserted-by":"crossref","unstructured":"Hofmeister, Liu, Bowers, Porcu, Flynn, Christian, Baiocchi, Benson, Andritsos, Greenfield, Sell, Geyer, Byrd, Grever. Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma. ASH Annual Meeting Abstracts. Abstract #2955. 2012.","DOI":"10.1182\/blood.V120.21.2955.2955"},{"key":"62","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1038\/bcj.2015.38","article-title":"Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma","volume":"5","author":"Anderson","year":"2015","journal-title":"Blood cancer journal"},{"key":"63","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nsmb.1576","article-title":"A feedback regulatory loop involving microRNA-9 and nuclear receptor TLX in neural stem cell fate determination","volume":"16","author":"Shi","year":"2009","journal-title":"Nature structural & molecular biology"},{"key":"64","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1073\/pnas.1302645110","article-title":"Critical role of miR-9 in myelopoiesis and EVI1-induced leukemogenesis","volume":"110","author":"Qian","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"65","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/eji.201142203","article-title":"miR-9 enhances IL-2 production in activated human CD4(+) T cells by repressing Blimp-1","volume":"42","author":"Pahl","year":"2012","journal-title":"European journal of immunology"},{"key":"66","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2353\/ajpath.2008.080009","article-title":"MicroRNA-mediated down-regulation of PRDM1\/Blimp-1 in Hodgkin\/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas","volume":"173","author":"Tam","year":"2008","journal-title":"Am J Pathol"},{"key":"67","doi-asserted-by":"crossref","first-page":"e77608","DOI":"10.1371\/journal.pone.0077608","article-title":"Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mousemodel of multiple myeloma","volume":"8","author":"Baughn","year":"2013","journal-title":"PLoS One"},{"key":"68","first-page":"235","article-title":"CD44, Hyaluronan, the Hematopoietic Stem Cell, and Leukemia-Initiating Cells","volume":"6","author":"Z\u00f6ller","year":"2015","journal-title":"Front Immunol"},{"key":"69","first-page":"S96","article-title":"Variance stabilization applied to microarray data calibration and to the quantification of differential expression","volume":"1","author":"Vingron","year":"2002","journal-title":"Bioinformatics"},{"key":"70","doi-asserted-by":"crossref","first-page":"R34","DOI":"10.1186\/gb-2003-4-5-r34","article-title":"Clustering gene-expression data with repeated measurements","volume":"4","author":"Bumgarner","year":"2003","journal-title":"Genome biology"},{"key":"71","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cell.2008.06.006","article-title":"Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression","volume":"134","author":"Weinberg","year":"2008","journal-title":"Cell"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T17:03:02Z","timestamp":1589389382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,25]]},"references-count":71,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2015,10,13]]}},"alternative-id":["5290","26429859"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.5290","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,25]]}}}